Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

POST-AUTHORISATION SAFETY COHORT OBSERVATION OF RETACRIT (EPOETIN ZETA) ADMINISTERED SUBCUTANEOUSLY FOR THE TREATMENT OF RENAL ANAEMIA (PASCO II)

NCT01543477 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01543477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01543477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
POST-AUTHORISATION SAFETY COHORT OBSERVATION OF RETACRIT (EPOETIN ZETA) ADMINISTERED SUBCUTANEOUSLY FOR THE TREATMENT OF RENAL ANAEMIA (PASCO II)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
July 7, 2010
Completion date
April 29, 2020
Enrollment
4,501 (actual)
Sites
179

Conditions

As the registry lists them; a condition with its own page is linked.

lactation, pregnancy, renal anemia